1. Scrip
  2. >>Business
  3. >>Deals

AstraZeneca Plans To Drug The Undruggable With Scorpion Partnership

Pays $75m Upfront

 
• By Ayisha Sharma

The UK major will work with the US biotech to develop up to three precision medicines targeting cancer proteins previously thought undruggable via conventional methods.    

Microscopic view of cancer cells. Cancer occurs when a cell's gene mutations make the cell unable to correct DNA damage.
The Partners Aim To Disrupt The Activity Of Highly-Validated Cancer Targets • Source: Alamy

AstraZeneca PLC will pay $75m to team up with Scorpion Therapeutics, Inc. and discover, develop and commercialize precision medicines against cancer proteins.

Under the terms of the agreement, Scorpion will continue to lead on discovery and preclinical research but the UK major has the exclusive option to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business